Ensuring patients with #cancer are well-informed about clinical trials is crucial! Proud to share our JAMA Oncology patient page, dedicated to ⬆️ inclusion & diversity in trial enrollment—#patienteducation is an important first step! 👥🔗 jamanetwork.com/journals/jamao… OncoAlert #lcsm

World Conference on Lung Cancer is an annual conference where the biggest brightest lung cancer experts share their cutting edge research in the fight against cancer. #WCLC is celebrating its 50 year anniversary making this an extra special golden-tie event!🥳🤩 #WCLC24

Spread #lungcancerawareness! Visit lungevity.org/AwarenessStore to order your customized shirt for #BreatheDeepTOGETHER. #Patients and #survivors receive a free shirt when they register for Breathe Deep TOGETHER! 🔗lungevity.org/together #BreatheDeep24 #lcam #lungcancer #lcsm

#WCLC24 kicks off September 7 with nearly 20 workshops for a wide range of specialties and interests. Learn more in #ILCN: bit.ly/4g4u6O3 #LCSM

Are you living with #smallcelllungcancer? Join us for a Facebook Live on9/13 as Anne Chiang (@yalemed) discusses the topic of breakthroughs in #sclc treatment. Tune in to Facebook.com/lungevity to watch! SmallCellSMASHERS #lcsm #lungcancer @iuhealth Misty Dawn Shields

Ivonescimab vs Pembrolizumab. For First line NSCLC. Harmoni-2 trial. Remember PFS is already declared postive as clinically meaningful. In both Squamous and Non Squamous histology and in both PDL1 low and high subsets . Full data on this Sunday at #WCLC24 This is going to be

Frequency of HER2 alterations across tumor types & current development landscape of HER2-targeted therapies summarized in this publication. nature.com/articles/s4157…

Have you dreamed of running the #BigSurInternationalMarathon? Great news, registration is now open! Run Big Sur w/ #TeamLUNGevity to check this race off your bucket list and help raise crucial funds for lung cancer research and support services. Sign up: brnw.ch/21wMqiU

Finally made it happen! An IRL meet up with the one and only Dr. Amy C. Moore. I love everything you and team LUNGevity Foundation are doing for our patients with lung cancer! Thank YOU!! #WCLC24

💥 The end of Pembro reign? Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: HARMONi-2 #WCLC24 #LCSM

John Heymach’s conclusions on discussing HARMONi-2. V nice overview and balanced discussion #WCLC24 IASLC

Are you caring for someone living with #lungcancer? #NoOneMissed has a #Caregiver Guide tailored to help all individuals supporting a loved one with #NSCLC. Explore the benefits of comprehensive #biomarkertesting together and download the guide today: brnw.ch/21wMsNP

#WCLC24 Presidential I Ph III HARMONI-2 ivonescimab v pembro in PDL>1% NSCLC: - 398pts - PFS HR 0.51 (11.1 v 5.82 mPFS) - benefit across histology & PDL1 🌟 Impressive data overall ❓Is this a step forward for PDL1 1-49% grp? 80% males enrolled, data needed in women IASLC

.Marina Garassino discusses approach to using TROP2 for predicting clinical response to Dato-Dxd in #NSCLC #WCLC24

Oral session at #WCLC24 on targeted therapy chaired by Drs. Prunella Blinman Xiuning Le MD PhD starts with Dr. Shirish Gadgeel with an update on MARIPOSA: first-line amivantamab (#EGFR #MET bispecific) plus lazertinib (approved by FDA August 19, 2024).

Let this sink in „1 Pet CT machine in the whole of West Africa“. Thanks Dr Shagaya for telling the Nigerian story #WCLC24

.Jill Feldman - breaking information into smaller pieces and sketching things out can help Effective communication is an absolute necessity for patient centred care #WCLC24

Hurray! Finally met LUNGevity Foundation awardee Coral Olazagasti, MD IRL! #WCLC24

Discussion of current management of SCLC by Dr. Estela Rodriguez and Eric K. Singhi, MD Oncology Brothers #WCLC24

Excited to spotlight Dr. Paulo G Bergerot’s e-poster at #WCLC24 His pilot study on exercise for lung cancer patients showed significant improvements in quality of life and symptom management. A huge step forward for exercise in oncology! 🌟 #LungCancer #WCLC50 #OncologyResearch